Position in NVAX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$875,560
+$125,777 QoQ
Shares Held
92,947
+0.9% QoQ
Ownership
0.056%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
#68
of 263 holders
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Palumbo Wealth Management LLC holds $18,521,472 across 32 Biotechnology names. NVAX ranks #5 (4.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABSI |
Absci Corp
|
183,193 | $2,123,206 | |
| 2 | DFTX |
Definium Therapeutics, Inc.
|
29,287 | $1,377,660 | |
| 3 | DSGN |
Design Therapeutics, Inc.
|
71,744 | $1,038,135 | |
| 4 | TSHA |
Taysha Gene Therapies, Inc.
|
149,173 | $1,015,868 | |
| 5 | NVAX |
Novavax Inc
This page
|
92,947 | $875,560 | |
| 6 | IDYA |
IDEAYA Biosciences, Inc.
|
23,198 | $864,589 | |
| 7 | SNDX |
Syndax Pharmaceuticals Inc
|
37,631 | $822,613 | |
| 8 | BEAM |
Beam Therapeutics Inc.
|
22,726 | $779,956 |
All Filings in NVAX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $875,560 | 92,947 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $749,783 | 92,111 | Shares | Defined | 2026-05-12 | |
| 2025-09-30 | $269,160 | 31,045 | Shares | Sole | 2025-11-10 | |
| No filing history on record for this holder in this stock. | ||||||